Online BusinessNovartis' swine flu vaccine show encouraging results
Swiss drug maker Novartis today said its newly developed vaccine "Celtura" against Influenza A HINI (Swine Flu) has shown effective result during a pilot test conducted by it.
- SC to hear Novartis case next week - Novartis moves SC against Glivec order - Novartis gains on hopes of flu vaccine order - Foreign pharma firms likely to beat Indian ones in developing vaccine - Novartis starts testing its swine flu vaccine - Novartis loses battle for cancer drug patent
The pilot test, done on 100 healthy volunteers aged between 18 and 50 by the Leicester University of Britain, has shown a protective immune response in case 80 per cent of the volunteers, administered with single dose of the vaccine, Novartis said in a statement.
The response in case of volunteers having two doses of vaccines was more than 90 per cent, it added.
"The pilot results are encouraging," Novartis CEO Vaccines and Diagnostics Andrin Oswald said, adding "the study suggests that while two doses seem to provide better protection, one dose of our adjuvanted Celtura vaccine may be sufficient to protect adults against the swine flu."
According to industry experts, a vaccine response of above 60 per cent can be termed as successful and has the potential to hit the market soon.
The swiss drug maker also said that more trials involving 6,000 volunteers including childrens are already under way.
However, the company has not provided details about the availability of vaccine in the market.
The Indian government has also written to global pharma giants including Novartis to conduct human trials of their newly-developed swine flu vaccines in the country, paving way for import.